stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) EV/EBITDA
As of 5 November 2026, TransMedics Group, Inc. (TMDX) trades at a EV/EBITDA of 22.0×. Over the past ten years it has ranged from 0.0× (June 2024) to 440× (August 2024); the current reading is higher than 70% of that period. That is above the Medical Devices industry median of 11.5× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 30.6× | (21.92%) |
| FY2024 | 39.2× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 26.0× | 14.26% |
| Jun 2026 | 22.8× | (24.01%) |
| Mar 2026 | 29.9× | (2.26%) |
| Dec 2025 | 30.6× | (4.01%) |
| 31 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| BFLY Butterfly Network, Inc. compare | n/m |
| ESTA Establishment Labs Holdings Inc. compare | n/m |
| NVCR NovoCure Limited compare | n/m |
| AXGN AxoGen, Inc. compare | n/m |
| ALMR Alamar Biosciences, Inc. compare | n/m |
| UFPT UFP Technologies, Inc. compare | 20.5× |
| TMDX TransMedics Group, Inc. | 22.0× |
| NEOG Neogen Corporation compare | 27.2× |
| INSP Inspire Medical Systems, Inc. compare | 48.4× |
| Medical Devices industry median | 11.5× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on TMDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement